1. Survival After Trimodality Therapy in Patients With Locally Advanced Esophagogastric Adenocarcinoma: Does Only a Complete Pathologic Response Matter?
- Author
-
Smita Sihag, Geoffrey Y. Ku, Kay See Tan, Abraham J. Wu, Yelena Y. Janjigian, Steven Brad Maron, David R. Jones, Laura H. Tang, Daniela Molena, Tamar B. Nobel, Manjit S. Bains, Sergio De La Torre, and Meier Hsu
- Subjects
medicine.medical_specialty ,Neoplasm, Residual ,Esophageal Neoplasms ,Locally advanced ,Adenocarcinoma ,Gastroenterology ,Article ,03 medical and health sciences ,0302 clinical medicine ,Major Pathologic Response ,Internal medicine ,Clinical endpoint ,Medicine ,Humans ,Stage (cooking) ,Survival analysis ,Retrospective Studies ,Neoplasm Staging ,business.industry ,Remission Induction ,medicine.disease ,Primary tumor ,Neoadjuvant Therapy ,Clinical trial ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Surgery ,business - Abstract
OBJECTIVE: To evaluate whether pathologic complete response (pCR) exclusively defines major pathologic response to treatment with improved survival. SUMMARY BACKGROUND DATA: pCR following trimodality therapy for esophagogastric adenocarcinoma is infrequent but associated with improved prognosis. Yet most clinical trials and correlative studies designate pCR as the primary endpoint. METHODS: We analyzed our prospectively maintained database for patients who underwent trimodality therapy for locally advanced esophageal adenocarcinoma between 1995 and 2017. Overall survival (OS) was examined by percentage treatment response (TR) in the primary tumor bed and pathologic nodal stage (ypN0) using Kaplan-Meier plots. Optimal thresholds of TR for differentiating patients in terms of OS were investigated with descriptive plots using restricted cubic spline functions; associations were quantified using Cox multivariable analysis. RESULTS: Among 788 patients, median follow-up was 37.5 months (range, 0.4–210.6); median OS was 48.3 months (95% CI, 42.2–58.8). Absence of residual nodal disease was independently associated with improved survival (P
- Published
- 2023